ArticleClinical drug investigation2022

Cost-Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective.

Andrea Carta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.